Lemonade, Inc.

NYSE:LMND Stock Report

Market Cap: US$1.7b

Lemonade Valuation

Is LMND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LMND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LMND's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LMND's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LMND?

Other financial metrics that can be useful for relative valuation.

LMND key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-7.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LMND's PS Ratio compare to its peers?

The above table shows the PS ratio for LMND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.4x
HCI HCI Group
1.7x8.4%US$1.2b
HG Hamilton Insurance Group
0.8x6.5%US$1.8b
EIG Employers Holdings
1.3x3.5%US$1.2b
TRUP Trupanion
1.9x5.0%US$2.3b
LMND Lemonade
3.5x24.0%US$1.7b

Price-To-Sales vs Peers: LMND is expensive based on its Price-To-Sales Ratio (3.5x) compared to the peer average (1.4x).

Price to Earnings Ratio vs Industry

How does LMND's PE Ratio compare vs other companies in the US Insurance Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: LMND is expensive based on its Price-To-Sales Ratio (3.5x) compared to the US Insurance industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is LMND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LMND PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: LMND is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LMND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.15
US$20.00
-17.2%
45.5%US$40.00US$11.00n/a7
Oct ’25US$16.15
US$19.14
+18.5%
46.0%US$40.00US$11.00n/a7
Sep ’25US$18.53
US$19.14
+3.3%
46.0%US$40.00US$11.00n/a7
Aug ’25US$17.30
US$19.29
+11.5%
46.0%US$40.00US$11.00n/a7
Jul ’25US$16.46
US$19.29
+17.2%
45.3%US$40.00US$11.00n/a7
Jun ’25US$16.51
US$19.29
+16.8%
45.3%US$40.00US$11.00n/a7
May ’25US$17.34
US$18.71
+7.9%
48.3%US$40.00US$10.00n/a7
Apr ’25US$16.56
US$18.43
+11.3%
49.8%US$40.00US$10.00n/a7
Mar ’25US$16.92
US$18.14
+7.2%
50.8%US$40.00US$10.00n/a7
Feb ’25US$16.18
US$18.00
+11.2%
51.6%US$40.00US$10.00n/a7
Jan ’25US$16.13
US$17.83
+10.6%
57.2%US$40.00US$10.00n/a6
Dec ’24US$18.30
US$17.71
-3.2%
53.4%US$40.00US$10.00n/a7
Nov ’24US$11.00
US$18.88
+71.6%
49.2%US$40.00US$9.00US$24.158
Oct ’24US$11.62
US$18.56
+59.7%
47.1%US$40.00US$9.00US$16.159
Sep ’24US$14.06
US$18.44
+31.2%
48.1%US$40.00US$8.00US$18.539
Aug ’24US$22.60
US$18.67
-17.4%
47.3%US$40.00US$8.00US$17.309
Jul ’24US$16.85
US$18.61
+10.5%
48.1%US$40.00US$8.00US$16.469
Jun ’24US$17.81
US$19.19
+7.7%
48.7%US$40.00US$8.00US$16.518
May ’24US$11.31
US$18.83
+66.5%
46.1%US$40.00US$10.00US$17.349
Apr ’24US$14.26
US$19.00
+33.2%
45.0%US$40.00US$10.00US$16.569
Mar ’24US$15.20
US$19.00
+25.0%
45.0%US$40.00US$10.00US$16.929
Feb ’24US$16.70
US$20.06
+20.1%
46.0%US$40.00US$10.00US$16.189
Jan ’24US$13.68
US$22.25
+62.6%
37.2%US$40.00US$14.00US$16.138
Dec ’23US$18.99
US$22.89
+20.5%
35.0%US$40.00US$14.00US$18.309
Nov ’23US$24.04
US$25.63
+6.6%
33.1%US$40.00US$14.00US$11.008

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y